share_log

Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023

Benzinga ·  Nov 15, 2023 06:41
  • Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors
  • Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024
  • Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,today provides a corporate update for the third quarter ending September 30, 2023 and to date:

Highlights:

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment